UNSPSC 51111815: Triptorelin

This classification denotes a gonadotropin-releasing hormone analog and anti-androgen with the molecular formula C64H82N18O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9081Y98W2V, chemically known as luteinizing hormone-releasing factor (pig), 6-d-tryptophan but generally known as triptorelin, which bears US NIH Compound Identifier 16129684. European Medicines Agency schedules Triptorelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11324MIG.

UNSPSC 51111815 Triptorelin, a Commodity code, covers generic pharmaceutical products supplied through state and local cooperative purchasing alliances to government facilities. The scope of work encompasses the manufacture and supply of FDA-compliant generic pharmaceuticals and over-the-counter products distributed via authorized wholesalers, with vendors required to maintain compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), provide electronic data interchange (EDI) capability, support multiple pricing formats (flat price, net price, WAC-minus), and maintain relationships with designated pharmaceutical wholesalers. Issuing bodies include multistate cooperative purchasing alliances and their member state agencies—in the most recent solicitation, the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals to serve participating state and local government facilities across multiple states including Oregon.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP (Solicitation S1070000015802) on January 20, 2026, seeking multiple awards for generic pharmaceuticals and OTC products with a proposal due date of March 26, 2026. Products must be available in the marketplace by May 15, 2026, with contract effectiveness beginning July 1, 2026, and the contract term running two years for new responders with optional extensions through June 30, 2028 for incumbents. Evaluation criteria weight price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing format (10 percent), administrative compliance and EDI capability (10 percent), and acceptance of a 3 percent administrative fee structure (5 percent). Vendors must maintain comprehensive insurance coverage including $5 million commercial general liability and $2 million network security and privacy liability, and submit pricing and product specifications through the ePro procurement system with detailed National Drug Codes (NDC), SKUs, and manufacturing location information.